Kyleena (Levonorgestrel)

Levonorgestrel released from Kyleena acts locally within the uterus. It thickens cervical mucus, reduces sperm motility and viability, and suppresses the growth of the endometrial lining, thereby preventing fertilization and implantation without requiring systemic hormone exposure.

The dose of levonorgestrel in Kyleena is fixed at 19.5 mg within the intrauterine system. The prescribing clinician determines the appropriate use and insertion schedule; no patient‑initiated dosing adjustments are required.

Kyleena is contraindicated in pregnancy and should not be inserted in a woman who is pregnant. For breastfeeding women, it may be used after the initial six‑week postpartum period, but clinicians often discuss alternative methods during early lactation.

To order Kyleena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with copper IUDs, Kyleena releases a low dose of levonorgestrel, which often results in reduced menstrual bleeding and fewer cramping episodes. Its hormone‑based mechanism offers contraceptive efficacy similar to other hormonal IUS devices while providing a smaller size suitable for a broader range of uterine dimensions.

Kyleena should be stored at room temperature, ideally below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures that could affect the integrity of the hormone reservoir.

Kyleena is inserted into the uterine cavity by a trained healthcare professional during a brief outpatient procedure. The device is placed through the cervix using a specialized inserter, after which the hormone‑releasing system remains in place for up to five years.

Serious risks include uterine perforation during insertion, device expulsion or displacement, pelvic inflammatory infection, and the rare possibility of ectopic pregnancy if fertilization occurs. Patients should seek immediate medical attention for severe abdominal pain, abnormal bleeding or signs of infection.

Kyleena is not recommended for women with active pelvic infections, unexplained vaginal bleeding, known or suspected uterine abnormalities, current pregnancy, or a history of breast cancer. Additionally, women who are allergic to levonorgestrel or any component of the device should avoid its use.